Breadcrumb Home investors investor resources Investor Resources Quick Explore Corporate Governance Shareholding Pattern Investor contact Year 2026-20272025-20262024-20252023-20242022-20232021-20222020-20212019-20202018-20192017-2018 Apply Schedule of Analysts/ Institutional Investor Meetings 27th Aug 2026 Allotment of 5,281 equity shares under ESOS 2013-A Scheme and the Cipla ESAR Scheme 2021 of the Company 26th Aug 2026 USFDA inspection at Company’s manufacturing facility in Pithampur, India 25th Aug 2026 NCLT Interim Order on Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited 19th Aug 2026 ESG Rating assigned by SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited 11th Aug 2026 Update on USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA 04th Aug 2026 Allotment of 7,850 equity shares under ESOS 2013-A Scheme and the Cipla ESAR Scheme 2021 of the Company 31st Jul 2026 Cipla Receives U.S. FDA Approval for Generic Advair Diskus® 27th Jul 2026 Earnings Call Transcript Q1 FY27 27th Jul 2026 Newspaper advertisement of Unaudited Financial Results – 30th June, 2026 24th Jul 2026 + BSE and NSE Quotes by TradingView The displayed data is not in real time and may have streaming delays.
